BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 11813932)

  • 21. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
    Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
    Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
    Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
    Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension.
    Lee DA
    Clin Ther; 2000 Jan; 22(1):53-65. PubMed ID: 10688390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
    Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
    Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure.
    Denis P; Baudouin C; Bron A; Nordmann JP; Renard JP; Rouland JF; Sellem E; Amrane M
    BMC Ophthalmol; 2010 Feb; 10():4. PubMed ID: 20181282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial.
    Fechtner RD; Myers JS; Hubatsch DA; Budenz DL; DuBiner HB
    Eye (Lond); 2016 Oct; 30(10):1343-1350. PubMed ID: 27367743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
    Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
    Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures.
    Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda F
    J Glaucoma; 2004 Apr; 13(2):149-57. PubMed ID: 15097262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the intraocular pressure lowering effect of latanoprost and carteolol-pilocarpine combination in newly diagnosed glaucoma.
    Ozdemir M; Ozdemir G
    Jpn J Ophthalmol; 2003; 47(1):72-6. PubMed ID: 12586182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily.
    Stewart WC; Stewart JA; Day D; Sharpe ED
    Acta Ophthalmol Scand; 2003 Jun; 81(3):242-6. PubMed ID: 12780402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
    Day DG; Hollander DA
    Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension.
    Netland PA; Michael M; Rosner SA; Katzman B; Macy JI
    Adv Ther; 2003; 20(1):20-30. PubMed ID: 12772815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
    Konstas AG; Karabatsas CH; Lallos N; Georgiadis N; Kotsimpou A; Stewart JA; Stewart WC
    Ophthalmology; 2005 Apr; 112(4):603-8. PubMed ID: 15808251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.